Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.

Medicine - 25 Jun 2021

Moore Assaf, Bar Yael, Maurice-Dror Corinne, Finkel Inbar, Goldvaser Hadar, Dudnik Elizabeth, Goldstein Daniel A, Gordon Noa, Billan Salem, Gutfeld Orit, Wolf Ido, Popovtzer Aron

Abstract excerpt

ABSTRACT: Radioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control.We analyzed all patients with IRTC and ATC who underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Chemoradiotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Israel

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Radiation Tolerance

Share to Thyroid Gland

Source

Open in PubMed Open full text

Identifiers

PMID: 34160418
DOI: 10.1097/MD.0000000000026388
PMCID: PMC8238320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.PMID 34160418Read ↗

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.Semantic proximity Read ↗

Single-cohort next-generation sequencing analysis of 713 anaplastic thyroid carcinomas: unreported gene alterations and actionable targets.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter studySemantic proximity Read ↗

Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.Semantic proximity Read ↗

Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Next-generation sequencing in thyroid cancer.Semantic proximity Read ↗

Update on the molecular diagnosis and targeted therapy of thyroid cancer.Semantic proximity Read ↗

Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome ProfilingSemantic proximity Read ↗

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.